Jericho Assisted Living
Wednesday, February 8, 2017
CardioBrief: Enormous NOAC Study Halted for 'Overwhelming Efficacy'
(MedPage Today) -- Rivaroxaban cut CV events in coronary and peripheral disease patients
via
CardioBrief: Enormous NOAC Study Halted for 'Overwhelming Efficacy'
by
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment